Questcor Eliminates Competition for H.P Acthar® Gel with Novartis Deal
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 7 (Table of Contents)
Published: 1 Jul-2013
DOI: 10.3833/pdr.v2013.i7.1957 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In order to acquire the main competitor to its key commercial product, Questcor Pharmaceuticals has outbid Retrophin to acquire rights to Synacthen® (tetracosactide) and Synacthen Depot® in more than three dozen international markets, including the US, from Novartis in a deal worth at least US$135 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS